HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO-B

457.600

+30.2007.07%

Volume:675.50K

Turnover:304.66M

Market Cap:106.71B

PE:-244.08

High:462.000

Open:424.400

Low:416.800

Close:427.400

52wk High:581.000

52wk Low:228.200

Shares:233.19M

HK Float Shares:162.77M

Volume Ratio:1.20

T/O Rate:0.41%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.875

ROE:-9.34%

ROA:-4.26%

PB:19.38

PE(LYR):-244.08

PS:45.82

Loading ...

Overview Company News Filings

HK Stock Movement | SKB BIO-B (06990) Rises Over 4% as ITGB6 and Another Drug Candidate Set for Phase I/II Monotherapy Trials in Q1 Next Year

Is Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Fairly Valued After Its 175% Year-To-Date Share Price Surge?

Simply Wall St.

Shipping Rates Soar 467% as Commodity Supply Routes Disrupted

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Partners With Crescent Biopharma

BUZZ-Crescent Biopharma jumps after cancer drug partnership

SKB BIO-B (06990) Forms Strategic Partnership with Crescent Biopharma to Co-Develop and Commercialize Oncology Therapies

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Company to Receive $80 Mln Upfront and up to $1.25 Bln in Milestones

THOMSON REUTERS

Crescent Biopharma and Kelun-Biotech Launch Strategic Oncology Partnership

Crescent Biopharma Inc - Kelun-Biotech Eligible for Milestones up to $1.25 Bln

THOMSON REUTERS

Crescent Biopharma Inc - Co to Receive $20 Mln Upfront Payment,Additional Milestones of up to US$30 Mln From Kelun-Biotech

THOMSON REUTERS

Crescent Biopharma Inc - Kelun-Biotech to Receive $80 Mln Upfront Payment,Additional Milestones of up to US$1.25 Billion From Crescent

THOMSON REUTERS

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

THOMSON REUTERS

Kelun-Biotech (06990) Announces Monthly Return for November 2025 with Unchanged Share Capital

Bulletin Express

Sichuan Kelun-Biotech (SEHK:6990): Unpacking Its Valuation After a 170% YTD Share Price Surge

Simply Wall St.

Kelun-Biotech Reports Promising Phase II Results for Sacituzumab Tirumotecan in Advanced Urothelial Carcinoma

Citic Securities Sets SKB BIO-B (06990) Target Price at HK$592, Maintains "Buy" Rating

JPMorgan Raises SKB BIO-B (06990) Target Price to HK$545, Reiterates "Overweight" Rating

HK Stock Movement | SKB BIO-B (06990) Rises Nearly 5% in Early Trading as SKB264 Phase III Trial Data Shows Positive Results; JPMorgan Raises Revenue Forecast

Hong Kong Stock Short Selling Data | November 25

Kelun-Biotech’s Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06990/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":457.6,"timestamp":1774598900006,"preClose":427.4,"halted":0,"volume":675495,"delay":0,"changeRate":0.07065980346279843,"floatShares":162769979,"shares":233185969,"eps":-1.8748004750340765,"marketStatus":"Closed","change":30.2,"latestTime":"03-27 16:08:20","open":424.4,"high":462,"low":416.8,"amount":304663116,"amplitude":0.105756,"askPrice":458.6,"askSize":78200,"bidPrice":457.6,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.8748004750340765,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":5,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":427.4,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"volumeRatio":1.200342,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":162769979,"roa":"-4.26%","roe":"-9.34%","lyrEps":-1.8748,"volumeRatio":1.200342,"shares":233185969,"dividePrice":0,"high":462,"amplitude":0.105756,"preClose":427.4,"low":416.8,"week52Low":228.2,"pbRate":"19.38","psRate":"45.82","week52High":581,"institutionHeld":0,"latestPrice":457.6,"committee":-0.987294,"eps":-1.8748004750340765,"divideRate":0,"volume":675495,"delay":0,"ttmEps":-1.8748004750340765,"open":424.4,"prevYearClose":392.2,"prevWeekClose":417.6,"prevMonthClose":387.4,"prevQuarterClose":392.2,"fiveDayClose":417.6,"twentyDayClose":387.4,"sixtyDayClose":405.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-18","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post Market","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"Post Market","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3684,"buy":0.6316,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6316,"analysts":19,"updateTime":1774540800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2026-03-26","current":-244.079307,"percent":0.142003,"low":-351.800852,"twenty":-170.083755,"median":-124.684843,"eighty":-50.855188,"high":-21.029201,"avg":-126.669321,"sd":76.954192,"marketCap":99663696400},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200},{"date":"2025-04-25","current":-235.137362,"twenty":-160.624501,"median":-68.953584,"eighty":-45.131919,"marketCap":66771338400},{"date":"2025-05-02","current":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"marketCap":78134738400},{"date":"2025-05-09","current":-249.374354,"twenty":-161.514906,"median":-70.050704,"eighty":-45.202208,"marketCap":71462875059},{"date":"2025-05-16","current":-247.507619,"twenty":-162.87029,"median":-70.732965,"eighty":-45.217068,"marketCap":71507400214},{"date":"2025-05-23","current":-244.618313,"twenty":-163.824551,"median":-71.32983,"eighty":-45.58151,"marketCap":70884048033},{"date":"2025-05-30","current":-244.159494,"twenty":-165.025774,"median":-71.669987,"eighty":-45.601984,"marketCap":71062148656},{"date":"2025-06-06","current":-258.187076,"twenty":-166.004403,"median":-72.203519,"eighty":-46.006494,"marketCap":75336563613},{"date":"2025-06-13","current":-271.678883,"twenty":-167.701589,"median":-72.488214,"eighty":-46.133909,"marketCap":79304691313},{"date":"2025-06-20","current":-252.757485,"twenty":-168.349452,"median":-72.789206,"eighty":-46.315126,"marketCap":73636805593},{"date":"2025-06-27","current":-255.806605,"twenty":-169.647858,"median":-73.569836,"eighty":-46.457129,"marketCap":74733815733},{"date":"2025-07-04","current":-283.173205,"twenty":-171.495185,"median":-73.869687,"eighty":-46.685504,"marketCap":82732847998},{"date":"2025-07-11","current":-266.231967,"twenty":-173.142078,"median":-74.539848,"eighty":-46.749361,"marketCap":77704884860},{"date":"2025-07-18","current":-304.526119,"twenty":-187.755426,"median":-75.01675,"eighty":-46.798833,"marketCap":88812112519},{"date":"2025-07-25","current":-289.211949,"twenty":-196.095673,"median":-75.38559,"eighty":-46.877904,"marketCap":84652615741},{"date":"2025-08-01","current":-318.351212,"twenty":-209.071662,"median":-75.715906,"eighty":-46.908544,"marketCap":92605939250},{"date":"2025-08-08","current":-315.832709,"twenty":-214.487876,"median":-76.34536,"eighty":-47.149906,"marketCap":92103142937},{"date":"2025-08-15","current":-340.637946,"twenty":-221.73884,"median":-77.157567,"eighty":-47.354138,"marketCap":99188000086},{"date":"2025-08-22","current":-135.707825,"twenty":-221.73884,"median":-78.335478,"eighty":-47.421279,"marketCap":106638527281},{"date":"2025-08-29","current":-131.473703,"twenty":-217.466422,"median":-78.819337,"eighty":-47.438439,"marketCap":103804584421},{"date":"2025-09-05","current":-151.82862,"twenty":-215.82299,"median":-80.340969,"eighty":-47.449348,"marketCap":119756940196},{"date":"2025-09-12","current":-146.494298,"twenty":-214.791029,"median":-81.555855,"eighty":-47.474394,"marketCap":115757424063},{"date":"2025-09-19","current":-147.466634,"twenty":-214.487876,"median":-85.53437,"eighty":-47.73502,"marketCap":116443055400},{"date":"2025-09-26","current":-143.954691,"twenty":-214.295448,"median":-89.950081,"eighty":-47.938811,"marketCap":113375018127},{"date":"2025-10-03","current":-165.853778,"twenty":-213.463042,"median":-128.34687,"eighty":-48.070155,"marketCap":130933921593},{"date":"2025-10-10","current":-144.531455,"twenty":-212.219938,"median":-131.729362,"eighty":-48.217901,"marketCap":113934664453},{"date":"2025-10-17","current":-135.703716,"twenty":-210.108236,"median":-132.867642,"eighty":-48.374971,"marketCap":106892448189},{"date":"2025-10-24","current":-129.499037,"twenty":-207.014216,"median":-133.546653,"eighty":-48.434282,"marketCap":102042180034},{"date":"2025-10-31","current":-132.379263,"twenty":-204.550971,"median":-132.326202,"eighty":-48.483234,"marketCap":104467314112},{"date":"2025-11-07","current":-120.930715,"twenty":-203.710245,"median":-131.985022,"eighty":-48.610423,"marketCap":95373061321},{"date":"2025-11-14","current":-137.099974,"twenty":-201.138492,"median":-131.729362,"eighty":-48.622244,"marketCap":108431475585},{"date":"2025-11-21","current":-125.836792,"twenty":-194.360264,"median":-130.233026,"eighty":-48.651606,"marketCap":99477134375},{"date":"2025-11-28","current":-134.139839,"twenty":-194.090443,"median":-131.64896,"eighty":-48.675637,"marketCap":106426076251},{"date":"2025-12-05","current":-134.965867,"twenty":-192.863217,"median":-131.473703,"eighty":-48.751223,"marketCap":107265545740},{"date":"2025-12-12","current":-128.449432,"twenty":-188.527876,"median":-130.526276,"eighty":-48.814858,"marketCap":102275366003},{"date":"2025-12-19","current":-122.479247,"twenty":-187.446049,"median":-129.499037,"eighty":-48.911385,"marketCap":97751558204},{"date":"2025-12-24","current":-122.098928,"twenty":-187.290368,"median":-128.758533,"eighty":-48.913338,"marketCap":97751558204},{"date":"2026-01-02","current":-116.223952,"twenty":-179.729041,"median":-128.478737,"eighty":-49.104524,"marketCap":93414299181},{"date":"2026-01-09","current":-137.872108,"twenty":-173.799059,"median":-128.508043,"eighty":-49.251224,"marketCap":111089795631},{"date":"2026-01-16","current":-136.67551,"twenty":-173.152374,"median":-129.252083,"eighty":-49.296233,"marketCap":110483512112},{"date":"2026-01-23","current":-124.044288,"twenty":-172.874196,"median":-128.511935,"eighty":-49.590244,"marketCap":100176692282},{"date":"2026-01-30","current":-119.398299,"twenty":-172.654145,"median":-128.43808,"eighty":-50.08289,"marketCap":96865451522},{"date":"2026-02-06","current":-121.3325,"twenty":-172.20913,"median":-127.906249,"eighty":-50.304899,"marketCap":98684302080},{"date":"2026-02-13","current":-119.328264,"twenty":-171.604872,"median":-127.229577,"eighty":-50.349599,"marketCap":97611646623},{"date":"2026-02-20","current":-118.929435,"twenty":-171.385498,"median":-126.777731,"eighty":-50.372821,"marketCap":97145274685},{"date":"2026-02-27","current":-109.393801,"twenty":-170.608939,"median":-126.362178,"eighty":-50.420375,"marketCap":90336244390},{"date":"2026-03-06","current":-109.941252,"twenty":-169.952459,"median":-125.237252,"eighty":-50.5225,"marketCap":90056421227},{"date":"2026-03-13","current":-111.874188,"twenty":-169.826622,"median":-125.028422,"eighty":-50.583009,"marketCap":92061820561},{"date":"2026-03-20","current":-118.784792,"twenty":-169.647858,"median":-124.510593,"eighty":-50.752344,"marketCap":97378460654},{"date":"2026-03-26","current":-230.435031,"twenty":-170.083755,"median":-124.684843,"eighty":-50.855188,"marketCap":99663696400}],"updateTime":1774620572713},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1139452041","title":"HK Stock Movement | SKB BIO-B (06990) Rises Over 4% as ITGB6 and Another Drug Candidate Set for Phase I/II Monotherapy Trials in Q1 Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1139452041","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139452041?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:28","pubTimestamp":1765420109,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) surged over 4%, reaching HK$427.4 by the time of writing, with a trading volume of HK$18.32 million. The company recently entered a collaboration with Crescent to jointly develop...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2589484388","title":"Is Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Fairly Valued After Its 175% Year-To-Date Share Price Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589484388","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589484388?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:21","pubTimestamp":1765149691,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has quietly been on a strong run this year, with the stock up around 175% year to date and roughly 150% over the past year.\nSee our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.\nThat kind of year to date share price return, combined with a 1 year total shareholder return of roughly 150 percent, signals that sentiment has swung sharply toward Kelun Biotech as investors price in faster growth and a lower perceived risk...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/is-sichuan-kelun-biotech-biopharmaceutical-sehk6990-fairly-v","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/is-sichuan-kelun-biotech-biopharmaceutical-sehk6990-fairly-v","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06990","LU0196878994.USD","BK1161","DCF"],"gpt_icon":0},{"id":"1107632191","title":"Shipping Rates Soar 467% as Commodity Supply Routes Disrupted","url":"https://stock-news.laohu8.com/highlight/detail?id=1107632191","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107632191?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:36","pubTimestamp":1764891391,"startTime":"0","endTime":"0","summary":"Shipping rates have surged by 467% as global commodity supply chains face disruptions. On December 3, the Baltic Dry Index (BDI) reached 2,845 points, marking its highest level since December 6,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","161715","000979.SH","02676","06990"],"gpt_icon":0},{"id":"2589399168","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Partners With Crescent Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589399168","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589399168?lang=en_us&edition=fundamental","pubTime":"2025-12-05 01:24","pubTimestamp":1764869080,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Partners With Crescent BiopharmaDec 4  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:PARTNERS WITH CRESCENT BIOPHARMACOMPANY TO RECEIVE $80 MILLION UPFRONT AND UP TO $1.25 BILLION IN MILESTONESFurther company coverage: 6990.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA021:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2588888137","title":"BUZZ-Crescent Biopharma jumps after cancer drug partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888137","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588888137?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:24","pubTimestamp":1764851056,"startTime":"0","endTime":"0","summary":"BUZZ-Crescent Biopharma jumps after cancer drug partnership ** Shares of drugmaker Crescent Biopharma CBIO.O rise 36.5% to $18.30 premarket ** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments** Co is also raising $185 million from investors to fund clinical trials - CBIO** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says** Up to last close, stock was down ~46% YTD   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL4N3XA0UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","BK4139","BK7509","IVX.AU","LU1064130708.USD","LU1064131003.USD","LU1979443071.USD","LU1934453819.USD","BK7096","BK0239","CBIO","BK0060","BK7508","LU0196878994.USD","002422","LU2148510915.USD"],"gpt_icon":0},{"id":"1107955650","title":"SKB BIO-B (06990) Forms Strategic Partnership with Crescent Biopharma to Co-Develop and Commercialize Oncology Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1107955650","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107955650?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:50","pubTimestamp":1764849025,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) announced that it has established a strategic partnership with Crescent Biopharma, Inc. and its wholly-owned subsidiary Crescent Biopharma Operating Company, LLC (collectively...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0329678337.USD","BK1583","06078","LU0329678170.USD","BK1161","LU0196878994.USD","LU2488822045.USD","LU0737861772.HKD","06990","BK1209"],"gpt_icon":0},{"id":"2588866818","title":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Company to Receive $80 Mln Upfront and up to $1.25 Bln in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2588866818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588866818?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:35","pubTimestamp":1764848119,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA021:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2588868458","title":"Crescent Biopharma and Kelun-Biotech Launch Strategic Oncology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588868458","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588868458?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847814,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. has announced a strategic partnership with Kelun-Biotech to jointly develop and commercialize novel oncology therapeutics. Under the terms of the collaboration, Crescent has granted Kelun-Biotech exclusive rights to research, develop, manufacture, and commercialize CR-001, a PD-1 x VEGF bispecific antibody, in Greater China, while Crescent has received exclusive rights to develop and commercialize SKB105, an integrin beta-6-directed antibody-drug conjugate , in the United States, Europe, and other markets outside Greater China. The partnership aims to advance both drug candidates as monotherapies and in combination, with both expected to enter Phase 1/2 clinical trials in early 2026. The collaboration is designed to accelerate development and maximize the potential of these therapies for cancer treatment globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4ZhvgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","06990","LU1934453819.USD","LU2095319765.USD","BK1161","LU0196878994.USD","IE00BKPKM429.USD","LU1064131003.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","NDAQ","BK0060","LU1064130708.USD","LU1979443071.USD","LU2148510915.USD","BK4588","002422","BK0239","CBIO","BK4585","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2588886556","title":"Crescent Biopharma Inc - Kelun-Biotech Eligible for Milestones up to $1.25 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886556?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["002422","CBIO","BK0060","BK1161","LU0196878994.USD","06990","LU1934453819.USD","LU2148510915.USD","BK0239","LU1064131003.USD","BK4139","LU1064130708.USD","LU1979443071.USD"],"gpt_icon":0},{"id":"2588886301","title":"Crescent Biopharma Inc - Co to Receive $20 Mln Upfront Payment,Additional Milestones of up to US$30 Mln From Kelun-Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886301?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2148510915.USD","06990","LU1934453819.USD","LU1064130708.USD","CBIO","BK1161","002422","BK4139","LU1979443071.USD","BK0239","BK0060","LU1064131003.USD","LU0196878994.USD"],"gpt_icon":0},{"id":"2588886300","title":"Crescent Biopharma Inc - Kelun-Biotech to Receive $80 Mln Upfront Payment,Additional Milestones of up to US$1.25 Billion From Crescent","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886300?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064130708.USD","BK4139","LU1979443071.USD","LU1934453819.USD","BK1161","CBIO","BK0239","BK0060","LU1064131003.USD","06990","LU2148510915.USD","002422","LU0196878994.USD"],"gpt_icon":0},{"id":"2588885002","title":"Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588885002","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588885002?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","002422","LU1979443071.USD","BK0060","BK4139","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK1161","CBIO","LU0196878994.USD","06990","LU1934453819.USD"],"gpt_icon":0},{"id":"1111664672","title":"Kelun-Biotech (06990) Announces Monthly Return for November 2025 with Unchanged Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1111664672","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111664672?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:16","pubTimestamp":1764839784,"startTime":"0","endTime":"0","summary":"Kelun-Biotech (06990) published its Monthly Return for Equity Issuer for November 2025. The document indicates that the total authorized share capital remains at RMB 233,185,969, with no changes in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"gpt_icon":0},{"id":"2587971557","title":"Sichuan Kelun-Biotech (SEHK:6990): Unpacking Its Valuation After a 170% YTD Share Price Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2587971557","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587971557?lang=en_us&edition=fundamental","pubTime":"2025-11-30 19:13","pubTimestamp":1764501190,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn attention among Hong Kong biotech stocks lately as investors look to its innovative drug pipeline and partnerships for potential growth opportunities, particularly following recent sector-wide movements.\nSee our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.\nSichuan Kelun-Biotech Biopharmaceutical has experienced remarkable momentum lately, with a year-to-date share price return of over 170%. This signals growing...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-sehk6990-unpacking-its-valuation-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-sehk6990-unpacking-its-valuation-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06990","BK1161","LU0196878994.USD","DCF"],"gpt_icon":0},{"id":"2586704672","title":"Kelun-Biotech Reports Promising Phase II Results for Sacituzumab Tirumotecan in Advanced Urothelial Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2586704672","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586704672?lang=en_us&edition=fundamental","pubTime":"2025-11-28 12:07","pubTimestamp":1764302841,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the publication of results from a Phase II clinical study evaluating sacituzumab tirumotecan  monotherapy in patients with advanced or metastatic urothelial carcinoma. The results, already published in the Annals of Oncology, are based on cohort 9 of the MK-2870-001/KL264-01 study and assess sac-TMT in patients whose disease progressed following chemotherapy and immune checkpoint inhibitors. Sac-TMT is a TROP2 antibody-drug conjugate that utilizes an irreversible conjugation technology with a novel topoisomerase I inhibitor payload . As of February 17, 2025, 49 participants were treated with sac-TMT. The confirmed objective response rate was 31%, with a disease control rate of 71% and a median progression-free survival of 5.5 months. The safety profile was considered manageable, with the most frequent grade 3 or 4 adverse events being hematologic toxicities and stomatitis. These results support further evaluation of sac-TM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL3sjPmN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1161","002422","LU2148510915.USD","LU1064130708.USD","LU0196878994.USD","LU1064131003.USD","LU1934453819.USD","06990","BK0060","LU1979443071.USD"],"gpt_icon":0},{"id":"1147469087","title":"Citic Securities Sets SKB BIO-B (06990) Target Price at HK$592, Maintains \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1147469087","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147469087?lang=en_us&edition=fundamental","pubTime":"2025-11-27 10:44","pubTimestamp":1764211459,"startTime":"0","endTime":"0","summary":"Citic Securities issued a research report stating that SKB BIO-B (06990) has gained recognition from multinational corporations (MNCs) for its core product, sacituzumab govitecan...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"1183337070","title":"JPMorgan Raises SKB BIO-B (06990) Target Price to HK$545, Reiterates \"Overweight\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1183337070","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183337070?lang=en_us&edition=fundamental","pubTime":"2025-11-25 15:50","pubTimestamp":1764057014,"startTime":"0","endTime":"0","summary":"JPMorgan has issued a research report expressing a more optimistic outlook on SKB BIO-B (06990), raising its revenue forecasts for 2025–2033 by 1%–10% and increasing the target price from HK$499 to...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"1140531356","title":"HK Stock Movement | SKB BIO-B (06990) Rises Nearly 5% in Early Trading as SKB264 Phase III Trial Data Shows Positive Results; JPMorgan Raises Revenue Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=1140531356","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140531356?lang=en_us&edition=fundamental","pubTime":"2025-11-25 11:38","pubTimestamp":1764041895,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) surged nearly 5% in early trading, reaching HK$469.6 with a turnover of HK$158 million by the time of reporting. The company recently released positive Phase III clinical trial data...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"1157125153","title":"Hong Kong Stock Short Selling Data | November 25","url":"https://stock-news.laohu8.com/highlight/detail?id=1157125153","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157125153?lang=en_us&edition=fundamental","pubTime":"2025-11-25 08:23","pubTimestamp":1764030183,"startTime":"0","endTime":"0","summary":"The latest short selling data for Hong Kong stocks shows the following key rankings as of November 25: **Top 3 Stocks by Short Selling Ratio**:   1. LENOVO GROUP-R (80992) – 87.71%   2. PING AN-R...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0054237671.USD","LU0823413587.USD","BK1184","LU1807302812.USD","LU0605514214.HKD","SG9999006514.SGD","BK1502","SG9999014898.SGD","LU0501845795.SGD","IE00B5MMRT66.SGD","BK1118","LU0127658192.USD","LU2237443895.HKD","BK1613","LU1051768304.USD","LU0417516902.SGD","IE00BQXX3F31.USD","LU0261950983.USD","LU0865486749.SGD","LU1242518931.SGD","LU0878005551.USD","00939","IE00BGHQDM52.EUR","LU0949170772.SGD","HK0000306685.HKD","LU0589944569.HKD","LU1196710864.SGD","BK4531","LU2237443382.USD","LU0211977185.USD","LU2476274308.USD","LU1303224171.USD","SG9999017495.SGD","09988","IE00B0JY6N72.USD","BK1560","HPAD.SI","LU1328615791.USD","SG9999014906.USD","BK1196","LU1226287529.USD","IE00BF5LJ272.USD","LU0029875118.USD","IE00B29SXG58.USD","BK1504","81024","LU1733274473.HKD","LU1064130708.USD","LU0449515922.USD","LU1044874839.SGD","LU0831103253.SGD","LU0165289439.USD","LU1781817850.SGD","IE0001KFT4U8.USD","IE0031814852.USD","LU0314109678.HKD","BK4575","LU0052756011.USD","LU0348814723.USD","LU0499858602.USD","LU2289578879.USD","LU1981816686.USD","HK0000165453.HKD","SG9999014914.USD","LU0786609619.USD","LU0048580855.USD","LU2097828474.EUR","BK1500","LU0197773160.USD","00839","LU0269904917.USD","09698","BK1608","IE00B3M56506.USD","LU0175139822.USD","BK0028","LU0070217475.USD","LU1044875133.USD","BK1161","IE00BZ08YT58.USD","LU1934453819.USD","LU0348827113.USD","LU0878004406.USD","IE00B067MR52.USD","LU0516423091.SGD","LU0898667661.SGD","LU2039709279.SGD","LU2476274720.SGD","LU0862451753.SGD","LU1003077747.HKD","LU2097828805.USD","LU2265009873.SGD","LU0642271901.SGD","LU2399975544.HKD","LU0106259558.USD","LU0828238088.HKD","LU1642822792.SGD","LU1226288097.SGD","BK4543","BK1229","LU1282649810.SGD","LU2498475776.HKD","SG9999000327.SGD","IE0032431581.USD","BK1591","HK0000320223.HKD","LU1196710351.USD","LU0890818403.SGD","LU0359201885.HKD","IE00B0169L03.USD","MIUmain","LU0469268626.HKD","LU1282649067.USD","LU0856984785.SGD","IE00BZ08YR35.GBP","LU1282648689.USD","LU1769817179.HKD","LU1804176565.USD","LU0882747503.HKD","LU1323998911.USD","LU1242518857.USD","SG9999014674.SGD","BK1556","LU0572940350.SGD","BK1604","LU1522347837.USD","LU0231483743.USD","IE0034224299.USD","LU0594300179.USD","SG9999000418.SGD","LU0640798160.USD","BK1561","LU0307460666.USD","LU0345776255.USD","IE00BZ08YS42.EUR","LU2226246903.HKD","LU1718418525.SGD","LU0047713382.USD","LU1251922891.USD","BK4579","LU0784639295.USD","LU0862451837.USD","LU0456842615.SGD","LU2148510915.USD","BK1516","LU0577902454.USD","LU0456846285.SGD","BK1167","LU0210533765.USD","LU0169518387.USD","LU1255011170.USD","LU0315178854.USD","LU1808992512.USD","IE00B97KM107.HKD","06993","LU1282651121.HKD","SG9999002828.SGD","01024","SG9999004220.SGD","LU2152927971.USD","BK4504","LU0543330483.HKD","LU0708995153.HKD","LU0516422440.USD","LU1868837722.USD","IE00BWDBJ730.SGD","LU1439103000.SGD","IE00B19Z5X02.USD","LU0541502299.USD","LU1497733631.SGD","BK1102","IE0008369823.USD","LU0791591158.USD","LU2023250504.SGD","LU0192582467.USD","LU0228367735.SGD","LU1960683339.HKD","LU1823568750.SGD","BK4535","LU1719994722.HKD","LU2106854487.HKD","LU0577902611.USD","LU2449936058.SGD","LU0823426308.USD","HTCD.SI","SG9999014880.SGD","BK4534","LU0261947096.USD","LU0327786744.USD","LU0359202008.SGD","LU1969619763.USD","LU1810669033.SGD","LU2328871848.SGD","LU2237443549.SGD","LU2348774022.SGD","BK1586","LU0823397285.USD","SGXZ90724238.SGD","LU1515016050.SGD","LU0163747925.USD","LU1997244956.HKD","LU0819121731.USD","BK0183","LU2495084118.USD","IE00B031HW06.USD","LU0348735423.USD","LU0553294199.USD","LU0572944931.SGD","LU0543330566.HKD","LU1868837565.USD","LU1048588211.SGD","LU0821914370.USD","LU0310800965.SGD","BK1618","601318","BK4505","09992","LU1814569148.SGD","LU0164872284.USD","LU2251237488.HKD","LU2362541273.HKD","BK1258","LU1770036033.HKD","LU0320764755.SGD","LU0823397103.USD","LU1051769294.HKD","SG9999002562.SGD","SG9999015952.SGD","TCHmain","LU0149721374.USD","02318","LU1046422090.SGD","BK0187","BK1614","BK1595","BK1590","LU0348784397.USD","LU0488056044.USD","LU0289960550.SGD","LU0588545730.USD","LU0823426480.USD","LU1769817096.USD","LU1951186391.HKD","LU1956131251.USD","01347","LU2097828714.EUR","LU1211504680.USD","LU1568876251.USD","LU1725190679.HKD","LU0315179316.USD","SG9999001846.SGD","80992","BK1517","BK1231","LU2148611432.USD","LU0164865239.USD","LU0972618739.USD","IE0003851619.USD","LU1655091616.SGD","IE00BVYPNP33.GBP","LU0080751232.USD","06099","LU0049853897.USD","IE0008368411.USD","BK4502","LU0072462343.USD","LU1146622755.USD","BK4220","LU0235996351.USD","LU0541501648.USD","LU1366334651.USD","LU1794554557.SGD","SG9999001093.SGD","IE00BGV7N243.SGD","LU1023057109.AUD","LU1115378108.SGD","LU0214875030.USD","82318","BK0070","LU1974910355.USD","LU1152091168.USD","LU0348825331.USD","LU0661504455.SGD","LU0979878070.USD","LU0633140727.USD","LU0516423174.USD","ALBmain","LU0052750758.USD","BK1507","LU0228659784.USD","LU0359201612.USD","LU0577902538.SGD","SG9999002463.SGD","BK4614","LU0264606111.USD","BK1609","SGXZ86797644.SGD","BK4554","IE0005HP3H50.USD","LU2543165471.USD","LU2778985437.USD","LU2293587155.HKD","BK4548","LU0823039010.USD","IE00B8L5B284.USD","LU2237443978.SGD","IE00B031J352.USD","BK1225","81810","LU1733274390.USD","LU0106252389.USD","LU0608807946.USD","SG9999015945.SGD","LU0043850808.USD","SG9999018865.SGD","LU0871576103.HKD","LU0708995583.HKD","LU0203347892.USD","BK4166","BK1193","LU1688375341.USD","LU2097828557.USD","LU0203345920.USD","LU0738912210.USD","LU1102505762.USD","LU0348805143.USD","00700","SG9999001226.SGD","LU2237443465.HKD","LU0287142896.SGD","LU0456827905.SGD","LU1831875114.USD","LU0188438112.USD","IE00BPRC5H50.USD","SG9999003461.SGD","LU0054450605.USD","06990","LU0797268264.HKD","BK1538","LU0819123356.HKD","BK0188","LU2097828631.EUR","LU1497734951.SGD","LU1880383440.USD","LU0329678170.USD","00546","LU0117841782.USD","LU0588545904.SGD","LU1497733557.USD","BK0012","LU0683595622.HKD","LU0762540952.USD","LU0499858438.USD","BABA","LU0516422366.SGD","LU0791590937.USD","LU0011963245.USD","LU1997245177.USD","BK4607","LU1366334578.USD","LU1048596156.SGD","LU1961090484.USD","LU1820825898.SGD","HK0000306701.USD","BK4581","00639","LU1064131003.USD","HK0000252160.HKD","LU0149534421.HKD","LU0320764599.SGD","IE00B543WZ88.USD","LU0061477393.USD","BK4558","LU0348766576.USD","LU0675040207.SGD","LU2242644610.SGD","LU0588546209.SGD","LU2087589342.USD","LU2153592121.USD","01810","SG9999015986.USD","LU0831093199.SGD","LU0611395673.USD","LU2008162690.USD","LU1226287792.SGD","IE00BMCWC346.EUR","LU0117844026.USD","LU0650527681.SGD","LU1152091754.HKD","LU1226288170.HKD","LU0251143458.SGD","KSTmain","BK4533","LU1188198961.HKD","LU1655091459.SGD","LU0128522744.USD","BK1526","LU0828237940.HKD","LU2362541513.USD","LU0531970944.HKD","LU0326950275.SGD","LU1044876610.USD","03145","BK4503","LU1196710195.USD","BK1134","IE00B8HQ1Z84.USD","BK1610","BK4538","02038","LU2125910500.SGD","LU1997245094.SGD","LU2177674079.SGD","IE00BQXX3D17.EUR","LU0128525689.USD","LU0417516738.SGD","LU3063872942.SGD","LU0531971595.HKD","LU0572939691.SGD","LU0143863784.USD","LU0251144936.SGD","BK1095","BK1228","LU0067412154.USD","HXXD.SI","09880","LU0048597586.USD","LU1568876335.HKD","LU0370786039.SGD","SG9999013353.USD","BK4527","LU0051755006.USD","LU1235295612.USD","LU0106959298.USD","SGXZ31699556.SGD","LU0384037296.USD","LU0828237510.HKD","LU0396098781.USD","BK1550","IE00BVYPNQ40.USD","LU0405327148.USD","LU0577902371.SGD","LU0348783662.USD","LU0651947912.USD","LU1439102457.SGD","LU2362540622.SGD","LU0072913022.USD","BK1521","BK1183","BK4565","LU1282651048.USD","BK4588","LU0029874905.USD","LU0449509016.USD","LU1224444064.USD","LU0823040885.USD","LU0608807433.USD","LU0329678337.USD","LU0348783233.USD","BK1583","SGXZ99366536.SGD","SG9999001903.USD","LU0762541174.USD","BK0207","LU1770034418.SGD","LU0229945570.USD","LU0593848301.USD","LU0985320562.USD","LU1267930227.SGD","LU0210526637.USD","BK4526","LU0738911758.USD","LU0345775950.USD","HK0000252152.HKD","LU1316542783.SGD","LU2247934214.USD","BK0175","IE0003795394.USD","LU0259732245.USD","SG9999001689.USD","LU1481107354.HKD","LU0140636845.USD","LU2237443622.USD","LU0211331839.USD","BK0196","LU0672654166.SGD","IE0003895053.USD","LU1785774172.SGD","LU0651946864.USD","00357","03143","BK1531","IE0032834883.USD","LU0049112450.USD","LU0634319403.HKD","LU1008478684.HKD","LU0630378429.USD","BK1224","LU0509642566.USD","LU2317271919.USD","LU1634259557.SGD","LU0918141887.USD","LU0164880469.USD","BK1506","LU1880383366.USD","LU0326948709.USD","BK0032","LU0417516571.SGD","IE00BQJZWZ67.USD","SG9999000459.SGD","LU0455707207.USD","LU0084288322.USD","LU2213484517.USD","LU0762542818.HKD","LU1675838814.USD","LU0441854154.USD","LU1046421795.USD","LU1282649141.HKD","BK1163","LU0196878994.USD","LU0414403682.SGD","LU0348816934.USD","PNGAY","LU0197773673.USD","LU0348723411.USD","BK1589","LU1629966141.USD","LU1226287875.USD","IE0008368742.USD","LU1224709979.USD","02602","LU0173614495.USD","LU0700851271.USD","PAImain","LU0545039389.USD","BK1585","LU1979443071.USD","LU0181495838.USD","LU0607220059.USD","LU0345769631.USD","LU1917777945.USD","LU","SG9999015978.USD","SGXZ81514606.USD","IE00B031HY20.USD","GB00BDT5M118.USD","LU2279701549.SGD","LU1720050803.USD","LU2051468812.USD","LU0348788117.USD","XIACY","LU0293314216.USD","LU1580142542.USD","BK1615","LU1235294995.USD","SG9999007991.SGD","SGXZ51526630.SGD","HK0000320264.USD","LU0648948544.HKD","LU0577902298.EUR","HK0000500386.USD","IE00BQXX3C00.GBP","LU0348767384.USD","LU2462611646.USD","IE00B0169N27.USD","LU0463099449.HKD","SG9999001051.SGD","LU0918141705.HKD","BK4122","LU0244354667.USD","LU0096374516.USD","LU0210527791.USD","LU0254981946.USD","IE00BYV24P56.USD","IE0009570106.USD","LU1813983027.USD","LU0823041008.USD","SG9999006597.SGD","LU1993786604.SGD","LU1048484197.HKD","LU2045819591.USD","LU0823413660.USD","LU0320764243.SGD","SGXZ62798434.SGD","LU2125910849.SGD","LU0737861772.HKD","LU0039217434.USD","LU0128522157.USD","LU1868838027.USD","LU0431992006.USD","LU0594300419.USD","LU0868486357.SGD","LU0886674414.USD","LU1734074674.USD","LU1328277881.USD","LU0345769128.USD","LU0633140560.USD","LU2133065610.SGD","LU0630378692.HKD","BK4524","LU2257852520.SGD","LU1634259391.SGD","LU1102505929.USD","LU0737861699.HKD","BK4585","BK4587","SG9999001069.SGD","BK1575","LU0107464264.USD","LU1504937902.USD","BK1523","BK1147","BK1564","IE00BFMHRM44.USD","SG9999018857.SGD","LU0502904849.HKD","BK1607","LU0143863198.USD","LU2251237306.USD","SG9999002950.SGD","LU1226288253.USD","LU0823038988.USD","LU0588545490.SGD","BK1588","LU0132412106.USD","BK1508","LU0328353924.USD","LU0048388663.USD","LU0516422952.EUR","LU0405327494.USD","LU0561508036.HKD","LU1883866441.USD","LU0873338254.USD","LU0540923850.HKD","LU1105468828.SGD","LU0880133367.SGD"],"gpt_icon":1},{"id":"2585461585","title":"Kelun-Biotech’s Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461585","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461585?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985636,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its Phase III clinical trial  evaluating sacituzumab tirumotecan  in combination with KEYTRUDA  as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer  has met its primary endpoint. The Independent Data Monitoring Committee reported a statistically significant and clinically meaningful improvement in progression-free survival , with a positive trend in overall survival also observed. This marks the first Phase III clinical trial of an antibody-drug conjugate combined with an immune checkpoint inhibitor to achieve its primary endpoint in first-line NSCLC treatment. The results have already been concluded as of the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5cqhCb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK0239","BK1161","LU1064131003.USD","002422","LU1064130708.USD","LU1934453819.USD","LU2148510915.USD","LU1979443071.USD","BK0060","LU0196878994.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":5,"totalSize":141,"code":"91000000","status":"200"}]}}